Design Medical, Inc. to Present at Medtech Insight's In3 EAST: "A Preview of Early-Stage Medical Technology Companies" Conference in Boston, Massachusetts.

Design Medical, Inc. Has Announced That It Will Be Presenting at Medtech Insight's In3 EAST: "A Preview of Early-Stage Medical Technology Companies" Conference at 12:20 p.m. on Thursday, October 19(th), at The Westin Copley Place Hotel in Boston, MA

BOSTON -- Design Medical, Inc. is an early stage medical device company that is developing a revolutionary heart pump that reduces complications following heart surgery. Current pumping technologies are a frequent cause of renal and neurological complications due to a failure to push blood through up to 40% of the capillaries. The Design Medical pump achieves superior flow and pressure performance, mimicking the physiological performance of the human heart - something no other pump does - in a unique, compact, economical, quiet, and robust package. Presently, pumps used in CPB are continuous flow and are incapable of delivering the gentle energy required to supply blood flow to critical organs. Our pumping system comprises a reusable driver and a high margin, single use disposable. The result is better patient care, with improved perfusion throughout all organs, thus reducing the negative complications of heart surgery, while passing on substantial savings to the hospital.

Our research reveals that 5%-10% of the 400,000 US heart surgery patients experience acute renal failure (ARF) after surgery. As a result, their length of hospital stay increases dramatically: they spend 22 days, on average, in the hospital, verses ~8 days, and have a 25% mortality versus ~1%. This increased length of stay and associated increased therapy costs are NOT covered--thus, the hospitals foot the additional bill. We believe that using our heart pump will greatly reduce the total number of patient days spent in the hospital as a result of post-surgical complications.

Recent feedback from several prestigious medical center cardiac surgery heads suggests that a rapidly growing segment of the CPB patient population at major medical centers has medical pre-conditions that would dictate the use of a pulsatile pump if one were available. The primary reason is that the rate of kidney failure in this population is 20+% verses 5-10% for the overall population. These pre-conditions include:

* Age > 70

* Congestive heart failure 

* Previous myocardial revascularization

* Diabetes Mellitus

* Elevated preoperative creatinine

Animal trials (porcine model) are the next step in our development path and we are currently engaged in a variety of conversations about the best way to conduct and fund this activity.

Contact Doug Vincent, President & CEO, 70 Bridge Street #7, Pelham, NH 03076-3419, Tel/Fax [phone] (or 978-805-3412), [e-mail].